Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy
Open Access
- 1 January 2018
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (1) , 120-122
Abstract
The treatment of anal cancer in patients who are seropositive for HIV (HIV-positive) has been controversial for more than 3 decades. Current treatment guidelines recommend that healthy HIV-positive patients receive standard fluorouracil and mitomycin C concurrent chemoradiotherapy, but some investigators question whether these patients experience more severe toxic effects or worse long-term outcomes that might necessitate a modified treatment approach. This study investigates the influence of HIV status on patient outcomes in a national cohort of US veterans.Keywords
This publication has 6 references indexed in Scilit:
- Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: Are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?Radiotherapy and Oncology, 2011
- Outcomes of Chemoradiotherapy With 5-Fluorouracil and Mitomycin C for Anal Cancer in Immunocompetent Versus Immunodeficient PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- HIV-Specific Differences in Outcome of Squamous Cell Carcinoma of the Anal Canal: A Multicentric Cohort Study of HIV-Positive Patients Receiving Highly Active Antiretroviral TherapyJournal of Clinical Oncology, 2008
- Human Immunodeficiency Virus–Associated Squamous Cell Cancer of the Anus: Epidemiology and Outcomes in the Highly Active Antiretroviral Therapy EraJournal of Clinical Oncology, 2008
- HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patientsDiseases of the Colon & Rectum, 2001
- Outcome analysis of HIV-positive patients with anal squamous cell carcinomaDiseases of the Colon & Rectum, 2001